Abstract:
PURPOSE: A pharmaceutical composition containing pyrrolopyrimidinone carboxamide derivative is provided to suppress Cdk1 and Cdk2 and to induce apoptosis of cancer cells. CONSTITUTION: A pyrrolopyrimidinone carboxamide derivative is denoted by chemical formula 1. A method for preparing the derivative comprises: a step of BSA to a compound of chemical formula 2 and adding a compound of chemical formula 3 under the presence of TMSOTf to prepare a compound of chemical formula 4; a step of adding ammonium hydroxide solution to the compound of chemical formula 4 to prepare a compound of chemical formula 5; and a step of adding hydrogen peroxide to the compound of chemical formula 5.
Abstract:
본 발명은 하기 화학식 1로 표시되는 피롤로피리미디논 카복사미드 유도체, 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 간세포암 예방 또는 치료용 약학적 조성물에 관한 것으로, 본 발명에 따른 피롤로피리미디논 카복사미드 유도체를 함유하는 조성물은 Cdk1 및 Cdk2를 억제함으로써 인간 간암세포주인 SNU-354 세포의 세포성장을 억제하고, Cdk7 및 Cdk9를 억제함으로써 상기 세포의 세포사멸을 유도하므로 간세포암의 예방 또는 치료에 유용하게 사용될 수 있다. [화학식 1]
Abstract:
PURPOSE: FeCrAl alloy containing aluminum is provided to enhance corrosion resistance and oxidation for a liquid Pb or Pb-Bi cooling material without serious brittleness within a temperature range of 300-600°C. CONSTITUTION: FeCrAl alloy containing aluminum consists of Cr of 9.5-12 weight% and Al of 4-5 weight%. The FeCrAl alloy forms an external protecting oxidizing layer. The oxidizing layer is an aluminum oxide layer(Al2O3). The FeCrAl alloy comprises Mo of 0.7 weight%, Zr of 0.03 weight%, B of 0.007 weight%, and C of 0.01 weight%. The FeCrAl alloy is used as the structural material and tubing material of an energy system including a nuclear reactor. The nuclear reactor is a liquid Pb and Pb-Bi cooling nuclear reactor.